Dimeric dipeptide mimetic GK-2 or hexamethylenediamide bis-(N-monosuccinyl-L-glutamyl-L-lysine), which activated TrkA receptors and exhibited neuroprotective activity in vitro (10–5 – 10–9 M) and in vivo (0.05 – 5 mg/kg i.p.), was designed by us earlier based on the beta-turn of the nerve growth factor (NGF) fourth loop. The effect of dimerizing spacer length on the manifestation of neuroprotective activity was studied by synthesizing GK-2 (11 σ-bonds) analogs tetramethylenediamide bis-(N-monosuccinyl-L-glutamyl-Llysine) (GK-2c); pentamethylenediamide bis-(N-monosuccinyl-L-glutamyl-L-lysine) (GK-2b); and trimethylenediamide bis-(N-monosuccinyl-L-glutamyl-L-lysyl-6-aminohexanoic acid) (GK-2a) containing 9, 10, and 22 σ-bonds, respectively, between the lysine Cα-atoms of the dipeptide fragments. Neuroprotective activity was investigated in vitro using HT-22 mouse hippocampal neuronal cell culture under H2O2-induced oxidative stress and showed that the neuroprotective activity as measured by the minimum effective concentration was 104 times less if the distance between the dipeptide fragments increased from 11 to 22 σ-bonds. The neuroprotective activity decreased insignificantly if this distance was decreased from 11 to 10 σ bonds (GK-2b) and disappeared with 9 σ -bonds (GK-2c). Therefore, the hexamethylene spacer was optimal although the distance between the corresponding amino-acid moieties of natural NGF from an x-ray structure analysis was considerably greater at 33 σ-bonds. This contradiction could have arisen because two ionically bound mimetic molecules interacted with TrkA receptors. Another possible explanation was that TrkA molecules could approach closer in the presence of bis-dipeptide GK-2 than NGF.
Similar content being viewed by others
References
L. Aloe, M. Rocco, B. Balzamino, and A. Micera, Curr. Neuropharmacol., 13(3), 294 – 303 (2015).
A. M. Colangelo, M. R. Bianco, L. Vitagliano, et al., J. Neurosci., 28(11), 2698 – 2709 (2008).
S. Maliartchouk, Y. Feng, L. Ivanisevic, et al., Mol. Pharmacol., 57(2), 385 – 391 (2000).
F. M. Longo, Y. Xie, and S. M. Massa, Curr. Med. Chem., 5(1), 29 (2005).
N. Q. McDonald, R. Lapatto, J. Murray-Rust, et al., Nature, 345, 411 – 414 (1991).
D. R. Kaplan and R. M. Stephens, J. Neurobiol., 25(11), 1404 – 1417 (1994).
S. B. Seredenin and T. A. Gudasheva, RU Pat. 2,410,392, Jan. 27, 2011; Byull. Izobret., No. 3 (2011).
T. A. Gudasheva, P. Y. Povarnina, T. A. Antipova, et al., J. Biomed. Sci., 22(5), 106 (2015).
K. Obata and K. Noguchi, Life Sci., 74(21), 2643 – 2653 (2004).
T. A. Antipova, T. A. Gudasheva, and S. B. Seredenin, Byull. Eksp. Biol. Med., 150(11), 537 – 540 (2010).
S. B. Seredenin and T. A. Gudasheva, Zh. Nevrol. Psikhiatr. im. S. S. Korsakova, 6, 63 – 70 (2015).
P. Y. Povarnina, O. N. Vorontsova, T. A. Gudasheva, et al., Acta Nat., 5(3), 84 – 91 (2013).
G. W. Anderson and J. E. Zimmerman, J. Am. Chem. Soc., 86(9), 1839 – 1842 (1964).
G. R. Jackson, K. Werrbach-Perez, E. L. Ezell, et al., Brain Res., 592(1 – 2), 239 – 248 (1992).
T. A. Gudasheva, A. V. Tarasyuk, I. O. Logvinov, et al., Bioorg. Khim., 38(3), 280 – 290 (2012).
N. M. Sazonova, A. V. Tarasyuk, D. V. Kurilov, et al., Khim. Farm. Zh., 49(7), 10 – 19 (2015); Pharm. Chem. J., 49(7), 439 – 448 (2015).
K. Riveles, L. Z. Huang, and M. Quik, NeuroToxicology, 29(3), 421 – 427 (2008).
Acknowledgments
The work was performed in the framework of a State Task (topic No. 0521-2019-0003, Search for pharmacological methods for selective activation of signal transduction pathways of tyrosine kinase neurotrophin receptors as platforms for designing drugs free of the adverse effects of native neurotrophins).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 53, No. 6, pp. 3 – 10, June, 2019.
Rights and permissions
About this article
Cite this article
Tarasyuk, A.V., Sazonova, N.M., Kurilov, D.V. et al. Synthesis and In Vitro Neuroprotective Activity of Analogs with Various Spacer Lengths of a Dimeric Dipeptide Mimetic (GK-2) of Nerve Growth Factor. Pharm Chem J 53, 487–494 (2019). https://doi.org/10.1007/s11094-019-02025-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-019-02025-9